While the animal studies showed C-31 acting alone in mimicking the effects of testosterone, Dalton hopes in the future to combine the candidate, or another SARM, with a progestin hormone. In this case, the progestin would shut down endogenous luteinising hormone, follicle-stimulating hormone and testosterone, thereby inhibiting sperm formation. The SARM would be given at a dose that would maintain muscle, bone and libido--an effect similar to combination hormonal treatments being studied.